Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Short Interest Update

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 226 shares, a growth of 465.0% from the June 15th total of 40 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 1,898 shares, the days-to-cover ratio is currently 0.1 days.

Orion OYJ Price Performance

Orion OYJ stock remained flat at $38.86 during trading on Friday. The company had a trading volume of 132 shares, compared to its average volume of 519. The company’s 50-day moving average price is $38.36 and its 200 day moving average price is $38.60. Orion OYJ has a fifty-two week low of $30.89 and a fifty-two week high of $42.75. The firm has a market cap of $10.97 billion, a PE ratio of 17.82 and a beta of 0.08. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.13 and a current ratio of 1.77.

Orion OYJ (OTCMKTS:ORINY) last released its earnings results on Thursday, April 23rd. The company reported $0.37 earnings per share (EPS) for the quarter. Orion OYJ had a return on equity of 49.17% and a net margin of 27.14%.The business had revenue of $488.80 million during the quarter.

Orion OYJ Company Profile

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.